Related Experiment Video
Updated: Jul 15, 2026
06:51
Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
Published on: July 21, 2021
Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms
Lisa Wright1, Xavier Barril, Brian Dymock
1Vernalis (R&D) Ltd., Granta Park, Abington, Cambridge CB1 6GB, UK.
Chemistry & Biology
|June 26, 2004
Summary
Targeting heat shock protein 90 (HSP90) with inhibitors like PU3 shows promise for cancer treatment. These compounds effectively inhibit cancer cell growth by blocking HSP90 function, as confirmed by structural and cellular studies.
Area of Science:
- Oncology
- Structural Biology
- Biochemistry
Background:
- Heat shock protein 90 (HSP90) is a molecular chaperone crucial for cancer cell survival.
- Inhibiting HSP90 ATPase activity is a validated strategy for cancer therapy.
Purpose of the Study:
- To determine the structures of HSP90alpha and HSP90beta N-terminal domains complexed with the inhibitor PU3 and its analogs.
- To provide a structural basis for understanding PU3's inhibitory mechanism and guide the design of improved cancer therapeutics.
Main Methods:
- X-ray crystallography was used to determine the complex structures.
- Enzyme-based and cell-based assays were employed to evaluate compound potency and mechanism of action.
Main Results:
- Structures of HSP90alpha-PU3 and HSP90beta-PU3 complexes were determined.
- PU3 analogs demonstrated enhanced potency in enzymatic and cellular assays.
- Inhibition of HSP90 led to upregulation of HSP70 and downregulation of client proteins (Raf-1, CDK4, ErbB2), confirming mechanism.
Conclusions:
- The determined structures provide a rationale for the binding affinity of PU3-class compounds to HSP90.
- These findings offer a structural framework for developing novel HSP90 inhibitors with improved binding and drug-like properties for cancer treatment.
More Related Videos
Related Concept Videos
01:30Enzyme Inhibition
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
02:04Protein-protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
00:49Ligand Binding and Linkage
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence the...
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:16Protein-Drug Binding: Mechanism and Kinetics
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...